Department of Oral Implantology, School and Hospital of Stomatology, Jilin University, Changchun, China.
Clin Oral Implants Res. 2022 Jul;33(7):700-712. doi: 10.1111/clr.13934. Epub 2022 May 7.
To evaluate patient-reported outcomes and radiographic results of simultaneous implant placement in severely atrophic maxilla using flapless endoscope-assisted osteotome sinus floor elevation with platelet-rich fibrin (PRF), also defined as PESS, and to compare the results with those of lateral sinus floor elevation (LSFE).
Patients with a residual bone height (RBH) of 2-6 mm were included in a randomised controlled trial. PESS was performed with PRF as the sole grafting material. LSFE was performed using deproteinised bovine bone matrix. Patient-reported outcomes were recorded on a visual analogue scale (VAS-pain) and visual rating scale (VRS-swelling and VRS-willingness). Peri-implant bone height (PBH), bone mineral density (BMD) and sinus grafting remodelling index were measured using CBCT immediately postoperatively and 3rd, 6th and 18th months post-surgery.
The study population consisted of 20 patients in each group. The RBH of two groups averaged 3.35 ± 0.79 mm and 2.92 ± 0.63 mm with no significant difference (p > .05). VAS-pain was 18.0 (IR 15.0-22.5) and 35.0 (IR 32.5-37.0) in the PESS and LSFE groups, respectively (p < .01). VAS-pain decreased with time in both groups. VRS-swelling was lower in the PESS group than LSFE group. VRS-willingness was higher in the PESS group than LSFE group (p < .01). At 18 months post-surgery, the marginal bone loss was 0.60 ± 0.25 mm and 0.69 ± 0.35 mm in the two groups with no significant difference (p = .52).
Within the limitations of this study, PESS was associated with lower postoperative morbidity and was more tolerable than LSFE. PESS could be a reliable procedure for sinus floor elevation in patients with insufficient RBH.
评估使用富含血小板纤维蛋白(PRF)的无瓣内镜辅助骨凿窦底提升(也称为 PESS)同时植入在严重萎缩的上颌骨中患者报告的结果和影像学结果,并与外侧窦底提升(LSFE)的结果进行比较。
将 RBH 为 2-6mm 的患者纳入一项随机对照试验。使用 PRF 作为唯一的移植物进行 PESS。LSFE 使用脱蛋白牛骨基质进行。使用视觉模拟量表(VAS-疼痛)和视觉评分量表(VRS-肿胀和 VRS-意愿)记录患者报告的结果。使用 CBCT 在术后即刻以及术后第 3、6 和 18 个月测量种植体周围骨高度(PBH)、骨矿物质密度(BMD)和窦腔植骨重塑指数。
每组 20 名患者纳入研究人群。两组的 RBH 平均为 3.35±0.79mm 和 2.92±0.63mm,无显著差异(p>.05)。PESS 和 LSFE 组的 VAS-疼痛分别为 18.0(IR 15.0-22.5)和 35.0(IR 32.5-37.0)(p<.01)。两组的 VAS-疼痛均随时间降低。PESS 组的 VRS-肿胀低于 LSFE 组。PESS 组的 VRS-意愿高于 LSFE 组(p<.01)。术后 18 个月,两组的边缘骨丢失分别为 0.60±0.25mm 和 0.69±0.35mm,无显著差异(p=.52)。
在本研究的限制范围内,PESS 与较低的术后发病率相关,并且比 LSFE 更耐受。PESS 可作为 RBH 不足患者窦底提升的可靠方法。